Merck Stock Pulls Back After Reaching New 52-Week High
Merck's stock price dipped 1.1% in pre-market trading after reaching a new 52-week high of $153.50.
The decline comes after Merck and partner Moderna announced positive results for their personalized mRNA cancer vaccine, intismeran autogene, combined with Keytruda, in a Phase 3 trial involving over 1,100 high-risk melanoma patients.
The vaccine met both primary and key secondary endpoints, including recurrence-free survival and distant metastasis-free survival, representing the first positive late-stage outcome for any mRNA-based cancer treatment.
Investors are re-evaluating the stock's valuation, with one framework indicating it is roughly 27% above its estimated intrinsic value. Insider selling trends also contribute to the perception that the stock is extended after a rapid appreciation.